Rare Case of Heart Failure and Encephalopathy from Cancer Treatment
Author Information
Author(s): Muacevic Alexander, Adler John R, Mikami Emi, Hashimoto Kosuke, Kaira Kyoichi, Mouri Atsuto, Miura Yu, Shiono Ayako, Yamaguchi Ou, Imai Hisao, Kagamu Hiroshi
Primary Institution: Saitama Medical University International Medical Center
Hypothesis
The combination of osimertinib and metronidazole in a patient with significant weight loss may increase the risk of adverse drug reactions.
Conclusion
The patient's significant weight loss likely increased blood concentrations of osimertinib and metronidazole, contributing to heart failure and encephalopathy.
Supporting Evidence
- The patient experienced significant weight loss during treatment, which may have increased drug toxicity.
- Osimertinib is known to cause heart failure in some patients.
- Metronidazole can lead to encephalopathy, especially in patients with altered pharmacokinetics.
Takeaway
A 78-year-old woman taking cancer drugs had serious side effects because she lost a lot of weight, which made the drugs stronger in her body.
Methodology
Case report detailing the patient's treatment and subsequent adverse effects.
Potential Biases
Potential bias in reporting due to the nature of a single case study.
Limitations
Only one case is reported, limiting generalizability.
Participant Demographics
78-year-old female with lung adenocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website